PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-57.23%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
5.53%
Positive EBIT growth while TRVN is negative. John Neff might see a substantial edge in operational management.
5.53%
Positive operating income growth while TRVN is negative. John Neff might view this as a competitive edge in operations.
5.62%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
13.79%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
13.79%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
10.10%
Share count expansion well above TRVN's 1.78%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.10%
Diluted share count expanding well above TRVN's 1.78%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth 1.25-1.5x TRVN's 16.62%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
17.73%
FCF growth similar to TRVN's 16.62%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Negative 10Y OCF/share CAGR while TRVN stands at 77.07%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
94.36%
5Y OCF/share CAGR 1.25-1.5x TRVN's 79.95%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
80.21%
3Y OCF/share CAGR above 1.5x TRVN's 6.75%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-551.14%
Negative 10Y net income/share CAGR while TRVN is at 74.77%. Joel Greenblatt sees a major red flag in long-term profit erosion.
94.20%
5Y net income/share CAGR 1.25-1.5x TRVN's 76.70%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
81.22%
3Y net income/share CAGR above 1.5x TRVN's 35.73%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1992.70%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-67.70%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-15.48%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.36%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
-16.56%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-15.08%
Our R&D shrinks while TRVN invests at 30.84%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.47%
We cut SG&A while TRVN invests at 43.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.